SA
Go ProLog In
AARD
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Hold
8 analysts·Limited coverage
59
Score
4 Buy (50%)3 Hold (38%)1 Sell (12%)
Rating Breakdown
Strong Buy
00%
Buy
450%
Hold
338%
Sell
113%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$3.00
-34.7%
Consensus
$20.50
+346.1%
Bull
$47.00
+922.9%
12-Month Target Range8 analysts
$3.00$20.50$47.00
Current $4.59Consensus
Current Price
$4.59
Upside to Consensus
$15.91

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+242.00%
EPS—
FY2028
Rev+543.09%
EPS—
FY2029
Rev+1248.36%
EPS—

Earnings Surprises

Recent Analyst Actions

May 15, 2026Morgan Stanley
Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley
Target:$3.00
-55.4%from $6.73
Mar 2, 2026RBC Capital
RBC Capital Downgrades Aardvark Therapeutics Inc (AARD) to Sector Perform
Target:$6.00
-52.0%from $12.49
Jan 12, 2026Raymond James
Raymond James Reiterates Strong Buy Rating on Aardvark Therapeutics Inc (AARD)
Target:$47.00
+229.4%from $14.27
Dec 23, 2025Oppenheimer
Aardvark Therapeutics initiated with an Outperform at Oppenheimer
Target:$35.00
+140.5%from $14.55
Nov 14, 2025RBC Capital
Aardvark Therapeutics Inc (AARD) PT Lowered to $18 at RBC Capital
Target:$18.00
+65.7%from $10.86
Sep 29, 2025Stifel Nicolaus
Aardvark Therapeutics initiated with a Buy at Stifel
Target:$24.00
+81.4%from $13.23
Mar 10, 2025Morgan Stanley
Aardvark Therapeutics initiated with an Overweight at Morgan Stanley
Target:$29.00
+190.6%from $9.98

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance